Trelegy Ellipta 62.5 ug/1

Trelegy Ellipta 62.5 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory use and is manufactured by GlaxoSmithKline LLC. This medication is commonly used for managing chronic respiratory conditions.

Trelegy Ellipta 62.5 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate works to reduce inflammation and improve breathing. This inhaler is often prescribed to individuals who require a combination of medications to manage their respiratory symptoms effectively.

Common effects of Trelegy Ellipta 62.5 ug/1 may include improved lung function and reduced symptoms such as wheezing and shortness of breath. Some users may experience side effects like headache, throat irritation, or a dry mouth. It is important to use this medication as directed by a healthcare professional to minimize potential side effects.

Trelegy Ellipta 62.5 ug/1 should be used with caution in individuals with a history of severe hypersensitivity to any of its components. It is important to follow the prescribed dosage and administration instructions to avoid overuse. Patients should also be aware of the potential for side effects and consult their healthcare provider if they experience any adverse reactions.

Trelegy Ellipta 62.5 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol consumption should be moderated while using this inhaler, as it may exacerbate some side effects.